CONNECT BIOPHARMA HOLDINGS LTD (CNTB)
Health Care · Biopharmaceutical development (monoclonal antibodies) · NASDAQ
Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD.
What CONNECT BIOPHARMA HOLDINGS LTD does
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation human monoclonal IgG4 antibody designed to target interleukin-4-receptor alpha (IL-4Rα) to inhibit IL-4 and IL-13 signaling in eosinophilic-driven respiratory diseases. In May 2025, the company initiated two Phase 2 trials: Seabreeze STAT ASTHMA and Seabreeze STAT COPD, evaluating rademikibart plus standard of care versus placebo in patients with acute exacerbations.
Themes: ["Asthma / acute exacerbations"]
Fundamentals
- Price$2.66 as of 2026-07-09 close
- Market cap$167M as of 2026-07-10
- 1-year return+96.5% as of 2026-07-09 close
- Net margin-21243.3% as of 2026-07-10
- ROE-122.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.23 as of 2026-07-10
Key risks (from latest filing)
["The company is in clinical-stage development with rademikibart in Phase 2 trials; failure to meet efficacy endpoints or safety requirements could prevent FDA approval and commercialization."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.